Latest Mergers And Acquisitions News

Bathurst Resources reports a dip in FY25 earnings due to lower coal prices and operational challenges but pushes forward with key development projects Buller and Tenas, targeting production growth from FY29.

MedAdvisor Limited reported a staggering $60.2 million loss for FY25, driven by operational challenges and asset impairments, while divesting its ANZ business and becoming debt-free.

4DMedical reports a robust 56% revenue increase in FY2025, driven by SaaS expansion and strategic partnerships, while advancing FDA clearance for its innovative CT – VQ™ lung imaging software.

betr Entertainment has lodged a formal application with the Takeovers Panel, contesting PointsBet’s board decision to accelerate vesting of performance rights amid competing takeover bids, a move that significantly boosted MIXI’s voting power.

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

Jayride Group Limited revealed a 55.5% plunge in revenue to $2.42 million for the fiscal year ending June 2025, alongside a reduced net loss of $5.7 million, signaling some financial stabilization despite ongoing challenges.

4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.

DorsaVi Limited reported a 13.9% revenue decline and a 21.7% rise in net loss for FY25, while securing over $3 million in capital to fuel new technology ventures.

Immuron Ltd reported a robust 49% increase in FY25 global sales, driven by strong Travelan® growth, while gearing up for a ProIBS launch and pivotal FDA meetings in 2025-26.

GALE Pacific reported a slight revenue dip and a net loss in FY25, driven by US market challenges including tariffs and weak consumer demand. The company is now overhauling its US operations and diversifying manufacturing to restore profitability.

Immuron Limited reported a strong 48.6% revenue increase driven by Travelan sales in Australia and North America, yet still recorded a $5.25 million net loss for FY25. The company’s cash reserves fell sharply, prompting a post-year capital raise.